The COPERNICUS trial: Beta-blockers in severe chronic heart failure [Classics Series]
1. Adding carvedilol to the management of patients with severe heart failure (NYHA Class III-IV and LVEF<25%) is associated with ...
1. Adding carvedilol to the management of patients with severe heart failure (NYHA Class III-IV and LVEF<25%) is associated with ...